Neox Clinical Research Opens its First US Office in San Diego
Neox Clinical Research, a Czech-based CRO, is pleased to announce they will be opening an office in San Diego, California in the first quarter of 2012 as their North American headquarters.
"Opening an office in the United States is a natural geographic addition for our overall global growth strategy. As we continue to add clients, backlog, feature sets and staff in the US it was an easy choice for us to open an office in San Diego," said Pavel Marek MD, CEO, Neox.
Heading up the US operations is Matt Delaney, Managing Director, Neox US Matt is an industry executive with more than 25 years of experience. Matt was previously Vice President of worldwide sales and marketing for a mid-size global CRO. "We are delighted to have Matt join the Neox team. Matt's experience in building and managing regions and teams will be a key ingredient for Neox's overall success", said Pavel Marek.
Neox also strengthens its management team in Europe. Jennifer Haggard, MS, has been hired to act as the Managing Director of Neox Europe. She is strategically located in a newly opened Neox office in Aachen, Germany. Jen has a long-lasting experience from both CRO and Pharma industries. "I believe that Jen is the key person for the overall management of European operations", said Pavel Marek. "I am delighted to be a part of the Neox team. Our experience conducting trials in CEE countries is significant and further expansion throughout Europe is paramount for Neox," Jen stated.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
